Trends in Microbiology
ReviewAntibodies against Candida: potential therapeutics?
References (41)
- et al.
J. Immunol. Methods
(1991) Trends Microbiol.
(1993)Vaccine
(1994)Vaccine
(1994)- et al.
FEMS Microbiol. Lett.
(1989) Immunol. Today
(1990)Biochem. Biophys. Res. Commun.
(1990)Comp. Biochem. Physiol.
(1995)- et al.
Med. Hypotheses
(1991)
Antibody Engineering
J. Clin. Microbiol.
Arch. Surg.
J. Am. Med. Assoc.
Sabouraudia
J. Immunol.
Immunology
J. Infect. Dis.
Mycopathologia
Cited by (47)
Structural characterization of low molecular weight polysaccharide from Astragalus membranaceus and its immunologic enhancement in recombinant protein vaccine against systemic candidiasis
2016, Carbohydrate PolymersCitation Excerpt :Thus, antifungal vaccines is currently considered the most attractive strategy (Brown et al., 2012Brown, Denning, & Levitz, 2012; Netea & Brown, 2012). It was reported that antibodies of 47 kDa antigen against epitope C (LKVIRK), which is a breakdown product of fungal heat shock protein 90 (HSP90), are protective in systemic candidiasis (Burnie & Matthews, 2003, 2004; Matthews & Burnie, 1996, 2001, 2005). The results from Matthews, Hodgetts, and Burnie, (1995) and Yang et al. (2005) further revealed that epitope C (LKVIRK) can confer protective immune responses against systemic candidiasis.
Water-soluble polysaccharide isolated with alkali from the stem of Physalis alkekengi L.: Structural characterization and immunologic enhancement in DNA vaccine
2015, Carbohydrate PolymersCitation Excerpt :Over the past two decades, morbidity and mortality of systemic candidal infection has increased significantly even in the presence of antifungal therapy (Gudlaugsson et al., 2003). Previous findings indicated that fungal heat shock protein 90 (HSP90) plays a key role in protection against systemic Candida albicans (C. albicans) infection (Burnie & Matthews, 2003, 2004; Matthews & Burnie, 1996, 2001, 2005). Consequently, we previously constructed the DNA vaccine (pD-HSP90C) containing epitope C (LKVIRK) of C. albicans HSP90 against systemic candidiasis, and found pD-HSP90C can evoke production of specific antibody against epitope C (LKVIRK) in mice (Yang, Han, Zhao, & Wang, 2014).
Immunoproteomic profiling of Saccharomyces cerevisiae systemic infection in a murine model
2015, Journal of ProteomicsCitation Excerpt :Taking into account that S. cerevisiae usually grows at temperatures lower than 37 °C, it is possible that at the first stages of the infection, heat shock proteins are induced for adaptation to the new environmental conditions inside the mouse. Several chaperones have been previously described as immunogenic proteins in different microorganisms [66,67] including C. albicans [38,51,56], and also related to a protective immune response against these pathogens [68,69], as for example, the production of Hsp90 antibodies during candidiasis [70,71]. Comparing the immune responses to D14 and W303 infection, the antibodies against heat shock proteins are present in sera against both strains, but it is apparent that they are much more abundant in serum from D14-infected mice.
A β-mannan trisaccharide conjugate vaccine aids clearance of Candida albicans in immunocompromised rabbits
2012, VaccineCitation Excerpt :Vaccine strategies to increase host resistance are attracting attention [7–11] because mortality due to Candida infections remains high despite antifungal therapy [12–15]. Experimental and clinical evidence shows the promise of acquired immunity in enhancing host defense mechanisms against the disease and the protective potential of antibody [16–20]. A successful vaccine in combination with antibiotic therapy could provide protection for individuals at high risk; such as patients scheduled to receive abdominal surgery; bone marrow, kidney or heart transplantations, immunosuppressive cancer therapy and those exposed to long-term hospitalization.
Anti-Candida antibodies and candidemia in ninety patients with HIV/AIDS and cancer
2007, Journal de Mycologie Medicale
- ∗
tel: +44 161 276 4660, fax: +44 161 276 8826